A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Principal Investigator Last Name
Awardee Organization
Awardee State
Contact PI Country
Project Detail
Funding Organization
Agency/Funding Organization
Funding Organization Country
Program Official